Loading...
Market
Vutrisiran sales exceed $500 million in first year?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Alnylam's financial reports and earnings releases
Story
Alnylam's Vutrisiran Achieves Positive Results in Phase 3 Study for ATTR-CM, Shares Surge 39%
Jun 24, 2024, 12:28 PM
Alnylam Pharmaceuticals reported positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The study achieved statistical significance on primary and all secondary endpoints in both overall and monotherapy populations, with a P-value around 0.01. Vutrisiran met its main goal of reducing deaths and recurrent cardiovascular events, paving the way for it to become the first RNA silencing therapy on the market for ATTR amyloidosis with cardiomyopathy. The results are seen as a significant advancement in the treatment of this rare heart condition, potentially creating a multibillion-dollar opportunity for Alnylam. Following the announcement, Alnylam's shares surged up to 39% in pre-market trading, eventually rising by 33% to 38%. The company plans to file for US approval later this year.
View original story
Similar markets
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 33%
Less than $500 million • 33%
$500 million to $1 billion • 33%
More than $1 billion • 33%
Exceeds $1 billion in sales • 25%
Between $500 million and $1 billion in sales • 25%
Between $100 million and $500 million in sales • 25%
Less than $100 million in sales • 25%
Vutrisiran leads • 25%
Acoramidis leads • 25%
Both have equal market share • 25%
Neither has significant market share • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%
FDA approval • 25%
New clinical trial results • 25%
Partnership with another company • 25%
No major announcement • 25%
